India's Concord Biotech jumps to 4-month high after US FDA drug approval
10/06/2026 07:18
BUZZ-India's Concord Biotech jumps to 4-month high after US FDA drug approval ** Shares of Concord Biotech CONB.NS jumps about 5% to 1,341.9 rupees, highest since February 9
** Co gets U.S. FDA abbreviated new drug application approval for Tofacitinib tablets, used to treat spondylitis, colitis and different forms of arthritis
** More than 615,960 shares traded so far vs 30-day average of 488,994 shares
** YTD, stock down 0.8%
(Reporting by Mridula Kumar in Bengaluru)
Recent news on Concord Biotech
See all newsIndia's Concord Biotech rises after board to consider bonus share issue
Brief: Concord Biotech Ltd June-Quarter Consol Net Profit 585.3 Million Rupees
Brief: Concord Biotech Completes PPB (Kenya) And NDA (Uganda) Inspection At Unit-Ii Formulation Facility
Brief: Concord Biotech Completes Anvisa Inspection At Limbasi API Manufacturing Facility
India's Concord Biotech jumps to 4-month high after US FDA drug approval